This is the most recent version of the national Cancer Drugs Fund list, and replaces any earlier versions. It contains updates to the previous list, as well as new drugs and indications which have been added to the Cancer Drugs Fund.
The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).
NHS England committed to a review of the evidence in relation to the treatment criteria for ibrutinib for previously treated patients with chronic lymphocytic leukaemia in June 2018. Following a call for evidence, NHS England’s Chemotherapy Clinical Reference Group (CRG) considered the evidence submitted and in this letter to Professor Stephen Powis, National Medical Director, NHS England, the CRG report their findings and make recommendations based on that evidence. Professor Powis has accepted the CRG’s findings and recommendations in full and consequently the treatment criteria will be updated in line with the recommendations. A commercial arrangement has been agreed with the manufacturer, Janssen to mitigate the financial impact of these changes.